← Back to homeRegeneron to Supply More Ebola Treatment Doses to U.S. Under $270 Million Deal
The expanded federal contract covers Inmazeb, which targets the Zaire species of Ebola, not the strain behind Africa's current outbreak.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources Brief
Regeneron said Monday it extended a 2020 agreement with the federal Biomedical Advanced Research and Development…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
2 sources behind this story.
By NewsPlain Editorial Team · Published
About this story
We haven’t published a correction to this story.
How NewsPlain works ← Back to home